Company Information

ASPIRA PATHLAB & DIAGNOSTICS LTD.

NSE : NABSE : 540788ISIN CODE : INE500C01017Industry : Hospital & Healthcare ServicesHouse : Private
BSE30.800.16 (+0.52 %)
PREV CLOSE ( ) 30.64
OPEN PRICE ( ) 30.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 380
TODAY'S LOW / HIGH ( )30.80 30.82
52 WK LOW / HIGH ( ) 22.7649.5
NSE
This Company is not listed in NSE
ChairmanHaseeb Drabu
Managing DirectorPankaj Shah
Company SecretaryKrupali Shah
Executive DirectorNikunj Mange
Non Executive Independent DirectorAvinash Chander Mahajan
Mangala Prabhu
Subhash Raghunath Salunke
Manas Mengar
Incorporation Year : 03-07 1973

Registered Office :

Address : Flat No. 2, R D Shah Building,Shraddanand Road, Opp. Ghatkopar Railway Station,Ghatkopar (West) Mumbai,
Maharashtra-400086 .

Phone : 022-7197 5756 / 2513 9090

Industry : Hospital & Healthcare Services

Listing : BSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.